Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset CRPS After TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. History of osteoarthritis~2. Subjects who can understand and communicate in English.~Exclusion Criteria:~1. Younger than 21 years or older than 80 years.~2. American Society of Anesthesiologists physical status IV.~3. Prior usage of gabapentin (or pregabalin) will not be an exclusionary criterion; however, patients will have been withdrawn from these medications for at least 7 days before surgery.~4. Patients with a history of neuropathic pain conditions.~5. Patients who are currently enrolled in another investigational study.~6. Pre-existing heart conditions~7. Patients on thiazolidinedione class of anti-diabetic medications (eg. rosiglitazone, pioglitazone).~   -

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 Placebo (Type: PLACEBO_COMPARATOR): Half of the patients will receive PO placebo for 14 days
- 2 Pregabalin (Type: EXPERIMENTAL): PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.

Based on this trial design, predict the completion outcome and termination type (if applicable).